Timely biomarker quantitation has potential to improve human health but current methods have disadvantages either in terms of cost and complexity for benchtop instruments, or reduced performance in quantitation and/or multiplexing for point-of-care systems. We previously developed microfluidic devices wherein visually observed flow distances correlated with a model analyte's concentration (Chatterjee et al., Anal. Chem., 2012, 84, 7057). Here, we significantly expand over this prior result to demonstrate the measurement of unamplified DNA analogues of microRNAs (miRNAs), biomarkers whose levels can be altered in disease states. We have developed a method for covalently attaching nucleic acid receptors on poly(dimethylsiloxane) microchannel surfaces by silane and cross-linker treatments. We found a flow distance dependence on target concentrations from 10 mg mL À1 to 10 pg mL À1 for DNA in both buffer and synthetic urine. Moreover, flow time in addition to flow distance is correlated with target concentration. We also observed longer flow distances for single-base mismatches compared to the target sequence at the same concentration, indicating that our approach can be used to detect point mutations. Finally, experiments with DNA analogues of miRNA biomarkers for kidney disease (mir-200c-3p) and prostate cancer (mir-107) in synthetic urine showed the ability to detect these analytes near clinically relevant levels. Our results demonstrate that these novel microfluidic assays offer a simple route to sensitive, amplification-free nucleic acid quantitation, with strong potential for point-of-care application.
Introduction
Biomarkers are disease indicators which can be found in body uids such as blood, saliva or urine and can indicate the disease state and/or progression characteristics.
1,2 The measurement of biomarkers is playing a growing role in early detection of disease, enabling improved treatment. Various biomarkers, including proteins, carbohydrates, lipids, hormones, metabolites and nucleic acids have been correlated with physiological responses to disease, injury, stress, etc. One class of analysis systems for biomarkers includes high performance benchtop instruments such as mass spectrometers (MS), 4, 5 liquid chromatography coupled to MS, 6,7 capillary electrophoresis coupled to MS, 7 Raman spectroscopy, 8 and nuclear magnetic resonance spectroscopy. 9 On the other hand, simplied systems include paper-based microuidics, [10] [11] [12] [13] blood glucose monitors, 14 lateral ow immunoassays, 15 and other point-of-care systems. 16 Many benchtop instruments have desirable performance characteristics such as good detection limits, accuracy, specicity, quantitation and/or multiplexing but the instrumentation is usually expensive and non-portable. In contrast, point-of-care systems are generally inexpensive and quick but lack several desirable performance characteristics such as good detection limits, quantitation capabilities (except for glucose monitoring 14 ) , and multiplexing. One important class of nucleic acid biomarkers is microRNA (miRNA), 19-24 nucleotide long, noncoding RNA that blocks translation of messenger RNA and hence plays a critical role in cell function. 17, 18 MiRNAs were rst described in 1993 by Lee and collegues. 19 MiRNAs are resistant to RNase activity, and are stable under both temperature and pH extremes, 17 such that conditions for miRNA analysis are somewhat less stringent than for other types of RNA. Furthermore, differential expression of miRNAs in many disease states combined with their presence in serum, plasma and other body uids, makes them promising biomarkers in early detection, classication, or prognosis of various illnesses including cancer, 20, 21 diabetes, 22 kidney disease, 23, 24 and liver disease. 25 For example, specic miRNAs are up-or down-regulated in cancer and thus have promise as biomarkers for cancer classication. 17 Mir-141 has elevated levels in the blood of prostate cancer patients, while mir-25 and mir-223 have increased serum levels in lung cancer patients compared to controls. 17 Moreover, differential expression of mir-126 and mir-182 in urine identied bladder cancer, 26 while mir-125a and mir-200a were detected at reduced levels in the saliva of oral squamous cell carcinoma patients compared to healthy controls. 27 Furthermore, mir-29a, mir-181a and mir-652 are potential breast cancer biomarkers, 28 while mir-21, mir-146a and mir-148a show promise to predict lymph node metastasis in gastric cancer.
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Accurate measurement of miRNA levels is important but the intrinsic characteristics of miRNAs such as low levels (fg mL À1 to pg mL
À1
), small size, sequence similarity, and difficulty in selective amplication make detection challenging. 30 Despite the difficulty, some methods have been developed for miRNA measurement. Quantitative reverse transcription PCR (qRT-PCR), which is the gold standard for sequence-specic RNA quantitation, does not work for miRNAs since they are about the same length as standard PCR primers. 31 However, modications of qRT-PCR using stem loop primers combined with TaqMan probes, 30 enable miRNA measurement with good dynamic range, 1000-fold better sensitivity than hybridization methods and reasonable target specicity. 30 Yet, this method needs probes, stem-loop primers and a reverse transcription step, all of which increase complexity and assay time. An amplication-based enzymatic bioluminescence miRNA assay 32 provides 10 pg mL
detection limits but the use of enzymes and their costs are downsides. In situ hybridization with locked nucleic acid probes 33 can determine native locations of miRNAs inside cells and tissues, but requires a uorescence microscope, and suffers from low throughput and high background signal. Microarray hybridization-based methods 34 for miRNA proling offer high throughput but require a labeling step for detection thus increasing complexity and cost. Liu et al. 35 recently detected miRNAs through graphene uorescence and switch-based cooperative amplica-tion, resulting in a 11 fM ($4 fg mL
) limit of detection; however, this method introduces complexity through amplication and labeling. Label-free miRNA detection methods involving nanopores 36 and surface plasmon resonance 37 have also been developed, with detection limits in the mid-fM range. Although sample preparation is simplied because labeling is not needed, sophisticated instruments and/or complex data interpretation are required, thus hindering their use in simple, point-of-care diagnostic settings. Importantly, present methods for miRNA analysis are in need of improvement; thus, as a step toward this we have focused on quantifying DNA analogues of miRNA.
We have developed a novel, label-free, sequence-specic nucleic acid quantitation method wherein the concentration is correlated with capillary ow distance of target solution in receptor-coated microuidic channels. Devices are made in an elastomer, poly(dimethylsiloxane) (PDMS), that has microuidic channels covalently derivatized with oligonucleotide receptors that are complementary to the target. Specic hybridization of target to receptors allows constriction through cross-linking of the top and bottom channel surfaces, as illustrated schematically in Fig. S1 in the ESI. † This concentration-dependent constriction relates target concentration with the capillary ow distance. Thus, target concentration can be determined readily from the capillary ow distance, which is easily measured through visual inspection. Our detection approach is much simpler than that of Tavares et al. 38 wherein distance measurement was also carried out, but required nucleic acid labeling and uorescence instrumentation. We have studied DNA analogues of miRNAs and found a ow distance dependence on target concentrations from 10 mg mL À1 to 10 pg mL À1 in both buffer and synthetic urine.
Furthermore, ow time in addition to ow distance is correlated with target concentration. Our approach offers the ability to detect very low target concentrations (10 pg mL
) and can discern single-base mismatches. Finally, we have analyzed DNA analogues of miRNAs linked to kidney disease and prostate cancer in synthetic urine samples and detected these analytes near clinically relevant levels ($5 pg mL
). 39 Our novel quantitation method's simplicity and cost effectiveness combines performance, selectivity and speed, thus demonstrating excellent potential for wide application in point-of-care nucleic acid biomarker diagnostics.
Experimental section
Mold preparation and PDMS device fabrication followed nearly the same procedures we published earlier, 40 but using a different positive photoresist, AZ4620 (AZ Electronic Materials, Branchburg, NJ). Although rounded microchannel cross sections were used as before 40 because of the ease of fabrication, alternate channel geometries such as sigmoidal or trapezoidal could be explored if more complex molds could be made readily. The microchannels in the devices used for ow distance experiments were 11 mm tall and 58 mm wide with a 0.5 mm PDMS top layer thickness. Other channel heights (7-18 mm) were used for initial surface modication optimization. All DNA oligonucleotides were obtained from Operon Biotechnologies (Huntsville, AL); names and sequences are given in Table 1 . Single-base mismatches were selected to demonstrate sequence specicity, rather than for clinical relevance.
Procedure for experimentation
The basic protocol for surface modication in the DNA sensing platform is outlined schematically in Fig. S2 in the ESI † and described below. 3-Aminopropyl-diisopropylethoxysilane (APDIES, Gelest, Morrisville, PA, 1-5% v/v in methanol) was lled via a combination of capillary action and/or vacuum in plasma-bonded PDMS microchannels of 7-18 mm heights. The silane was allowed to attach covalently to the PDMS channel walls for 30-60 min, leaving exposed amine groups (see Fig. S2B †). Then the APDIES solution was removed and the channels were ushed with phosphate buffered saline (PBS, 10 mM, pH 7.2) to remove unattached material. Next, PBS was aspirated from the channels and glutaraldehyde solution (Sigma-Aldrich, St. Louis, MO, 0.5-8% v/v in water) was added to the channels to react with APDIES amine groups, as seen in Fig. S2C , † for 30-60 min. Then the glutaraldehyde solution was removed and channels were once again ushed with PBS. Some initial experiments with (3-glycidyloxypropyl)trimethoxysilane (GOPS, Sigma-Aldrich, 1-10% v/v in methanol) instead of APDIES were also conducted using the same protocol as above but without glutaraldehyde reaction with the silanized surface. Next, PBS was aspirated from the channels and 2 mL of a 2 mg mL À1 amine-modied DNA oligonucleotide solution (50/50 mixture of two receptor sequences in 10 mM PBS) was lled in the channels by capillary action followed by 1 hour incubation to react with the free aldehyde in glutaraldehyde. Aer this, channel emptying followed by rinsing with PBS were done as above. During all the incubation steps, the devices were stored in a humidied ambient to prevent drying. Aer emptying the channel by applying vacuum, 1 mL of DNA target solution of specied concentration in PBS or simulated urine (VWR, West Chester, PA) was pipetted into the reservoir. The ow distance of the target solution in the microchannel was measured with a ruler, and photographs of the devices were obtained with a digital camera. Experiments for determining ow distance as a function of time were also performed with buffer (no DNA) or target solutions; ow distance was measured every 10 seconds until the uid receded back to the sample introduction point. Experiments with mismatched sequences (see Table 1 ) of specied concentration in PBS were conducted under the same protocol as for the complementary DNA target. Also, experiments were conducted with DNA analogues of miRNA, mir-200c-3p and mir-107, in PBS and simulated urine with their respective amine-modied receptors attached to channel surfaces (see Table 1 ).
Results and discussion
We studied nucleic acid sensing in a ow distance microuidic platform. We measured the ow proles of target and control (buffer) solutions as a function of time in the derivatized microchannels. In addition, we characterized the maximum ow distances for different concentrations of various DNA oligonucleotides, including a complementary DNA target sequence, single-base and fully mismatched sequences, and DNA analogues of miRNA targets. 
40 however, in the current studies, the shorter 11 mm height channels in combination with solution evaporation led to only partial channel lling. In either case the ow distance can readily be determined by visual examination. Fig. S3C and S3E † show shorter ow distances for 10 mg mL À1 model target DNA concentrations in buffer and synthetic urine respectively, while Fig. S3D and S3F † show longer ow distances for 10 ng mL
À1
(lower concentration) model target in these same matrices. These results agree with our expectation that higher target concentrations cause more rapid channel constriction which leads to shorter ow distances, while lower target concentrations result in slower channel constriction that yields longer ow distances, as we showed previously.
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In initial experiments we derivatized microchannels with GOPS in an effort to attach amine-modied DNA receptors to plasma-oxidized microchannels. In a 13 mm tall channel functionalized with 1% GOPS and treated with model receptors 1 and 2 (see Table 1 ), a high concentration (700 mg mL À1 ) of model target solution travelled 130 mm, a much longer ow distance than we observed for similar concentrations and channels in earlier work involving biotin-streptavidin. 40 We hypothesized that perhaps either a higher GOPS concentration or shorter channel height would decrease the ow distance. However, increasing the GOPS concentration to 8% or reducing the channel height to 7 mm still resulted in a 130-140 mm ow distance for 700 mg mL À1 solutions of model target. Furthermore, different incubation times (30-180 min) for GOPS were tried, but likewise yielded similar ow distances for the same concentration of model target. From these experiments we concluded that GOPS and amine-linked DNA coupling did not work well in our system, possibly because the reactive epoxy ring had been partially deactivated (before exposure to DNA) by ring opening in the presence of water or methanol -OH groups.
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Another reason for poor results with GOPS could be that it is a tri-alkoxy silane 42 that can form branched or cross-linked structures that result in multiple layers and poorer uniformity in the coating.
Given the difficulties encountered with GOPS, we also tried surface functionalization with APDIES along with a cross-linker (glutaraldehyde) for receptor attachment. APDIES has just one surface-reactive alkoxy functional group, which results in channel coating with a maximum of a monolayer of silane. 42 In 13 mm tall channels modied using 2% APDIES and glutaraldehyde concentrations of 2%, 5% and 8%, the ow distances for 1-10 000 ng mL À1 model target solution are given in Fig. S4 in the ESI. † We observe two trends in the data: rst, for a given concentration of model target, the ow distance decreases with increasing concentration of the glutaraldehyde cross-linker used in derivatization; second, more marked dependence of ow distance on concentration is observed with increasing glutaraldehyde concentrations. We hypothesize that increased numbers of receptor attachments on the channel surface with higher cross-linker concentrations provide more targetreceptor interaction, resulting in more rapid channel constriction and shorter ow distances. With 2% glutaraldehyde, there is little ow distance dependence on concentration. With 5% and 8% glutaraldehyde, there is some ow distance dependence on concentration, and the change in ow distance for each 10-fold concentration change is greater for 8% glutaraldehyde. Thus, 8% glutaraldehyde solution was used for surface derivatization because of the greater sensitivity of ow distance to changes in DNA concentration. We note that solutions with glutaraldehyde concentrations over 8% were so viscous that ow through 13 mm tall channels during successive steps was irreproducible, making further increases in glutaraldehyde concentration impractical. Imine bond formation by reaction of an aldehyde with amine-modied DNA, although less robust than the same linkage aer cyanoborohydride reduction, provides simple and direct receptor attachment with adequate stability for subsequent surface characterization.
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In 13 mm tall microchannels modied with receptors, 1 ng mL À1 model target solutions in buffer owed distances close to those of buffer lacking DNA (130-140 mm). We found that microchannel heights of 11 mm allowed us to determine DNA target concentrations even lower than 1 ng mL À1 , so this channel height was used in subsequent work. Experiments were conducted to determine ow distance as a function of time for solutions (with or without DNA) travelling through receptor-coated, 11 mm tall microchannels. Fig. 1 shows the ow distances for buffer (lacking DNA) and model target DNA (1 mg mL À1 and 1 ng mL À1 ) in buffer, as a function of ow time in microchannels coated with model receptors 1 and 2. The ow distance for buffer, which does not interact with receptors, increases with ow time until reaching a plateau at 123 mm ow in $180 seconds. In contrast, the model target in solutions interacts with the surface receptors which constricts the channel ( Fig. S1B and S1D †), and slows the ow velocity. Thus, 1 ng mL À1 target takes $450 seconds to travel 80 mm where it stops, compared to $60 seconds for buffer solution to travel the same distance. Also, 1 mg mL À1 model target takes $180
seconds to travel 32 mm where it stops, versus 20 seconds for buffer and 90 seconds for 1 ng mL À1 model target to travel the same distance. In all experiments, aer ow stops the uid position is maintained for another $3 min, aer which the liquid recedes back to the sample introduction point due to evaporation. We note that this 3 min "plateau" in ow gives ample time for distance measurement. Fig. 2 shows a plot of this maximum ow distance as a function of ow time for different model target DNA concentrations. Lower model target concentrations have greater maximum ow distances and ow times. Thus, ow time, in addition to ow distance, 40 could be used to determine the concentration of target in a solution owed in our devices.
Experiments involving several mismatched sequences were done using 11 mm tall microchannels coated with model receptors 1 and 2. Fig. 3 shows the ow distance as a function of logarithm of DNA concentration for the model target and ve mismatched sequences. For the model target sequence the ow distance has a linear correlation with the logarithm of target concentration. The lowest detected model target concentration was 10 pg mL À1 with a mean ow distance of 118 mm, appreciably less than the buffer (no DNA) mean ow distance (128 mm). The total mismatch sequence ows greater distances (nearly the same as buffer, except for the 10 mg mL À1 solution)
than all the other sequences, indicating that the surfaceattached model receptors 1 and 2 do not bind appreciably with the total mismatch sequence in solution owing through the channel. This result demonstrates the specicity of our system in distinguishing between complementary and non-complementary sequences. Because of this signicant difference in ow properties, we decided to test the ultimate in sequence specicity: single-base mismatches. Thus, we tested ow with oligonucleotides that differed from the target only at the 6th position from the 5 0 end or at the 6th position from the 3 0 end.
As seen in Fig. 3 , many mismatched sequences had 10-40 mm longer average ow distances than the model target, but shorter ow distances than the total mismatch at each concentration. These longer ow distances for mismatched sequences are driven by their lower energy of hybridization compared to that of the complementary sequence. Our results show that the position of the base mismatch is important in generating a distinct ow distance from the complementary sequence. For example, a single-base mismatch at the 2nd base from the 3 0 end of model receptor 1 resulted in longer ow distances than a similar mismatch at the 2nd base from the 5 0 end of this same receptor. Although a more comprehensive study of the effects of mismatches on ow distance should provide further information, our results demonstrate that the binding of surfaceattached receptors to target is affected by a difference of just one base in the sequence. Thus, our approach can be used to differentiate between single-base mismatch point mutations which are oen the cause of genetic disorders.
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Fig . 4 shows ow distances in receptor 1 and 2 modied microchannels as a function of logarithm of model target concentration in buffer and synthetic urine. A linear correlation is seen between ow distance and logarithm of target concentration in both buffer and in synthetic urine, which should enable direct quantitation from the easily measured ow distance. Moreover, the linearity is maintained over a 10 6 -fold range of concentrations indicating a wide dynamic range. The lowest concentration of target DNA detected is 10 pg mL À1 , indicating a 100-fold improvement over what we achieved previously for biotin-streptavidin. 40 Importantly, the lowest concentrations measured in our simple system are as much as 1000-fold lower than in other simple diagnostics such as paperbased microuidic systems that can detect in the high nM range.
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Given these detection capabilities, we also tested DNA analogues of a kidney disease miRNA biomarker, mir-200c-3p, 39 and a prostate cancer miRNA biomarker, mir-107, 45 in buffer and synthetic urine (Fig. 5) . As with previous nucleic acid targets, there is a linear correlation between ow distance and logarithm of nucleic acid concentration with both biomarkers. The lowest concentration detected for both biomarkers is 10 pg mL À1 , which is near the actual concentrations of these miRNAs in urine ($5 pg mL À1 ). 39 We see a small increase in the standard deviations of slopes and intercepts of these plots compared to the results for the model target (Fig. 4) , perhaps due to higher GC content in the miRNA analogues ($48% versus 40%). The miRNA analogues are also one base longer than the model target, but this seems less likely to increase scatter in the data. Importantly, we have shown the ability to detect analogues of signicant miRNA biomarkers in a similar matrix and at levels near those that are clinically signicant, demonstrating strong potential for application of our system in quantifying miRNA and other nucleic acids in medical applications.
To move from our present work to miRNA detection in biological samples will require additional advances. First, although miRNAs are resistant to RNase digestion, greater care would likely need to be taken in device and solution preparation. Second, miRNAs are present in exosomes in urine, so methods are needed for making the miRNAs available for hybridization. One method to release miRNA to enable hybridization would be to add a surfactant (or organic solvent) to the urine sample, which would emulsify the exosome lipid bilayer. The viscosity of normal (or diabetic) urine is $1.2 fold greater than that of water, with a range in viscosity of $20% over 14 samples, while urine with up to 1% albumin has a viscosity 1.3-1.6 times that of water. 46 We previously found that ow distances in our devices were unaffected (within experimental uncertainty) by viscosity unless it was increased by more than a factor of 2 over that of water. 40 Thus, the viscosity of most urine samples is in a range where ow distances in our devices should be independent of viscosity. Given these considerations, it should be possible to measure miRNA directly from biological uids such as urine thus showing great potential for point-of-care diagnosis.
Conclusions
We have developed a simple, microfabricated ow-based system for sequence-specic nucleic acid quantitation in biological matrices. We have covalently attached oligonucleotide receptors on poly(dimethylsiloxane) microchannel surfaces through combined silane and cross-linker treatments. We found that ow time in addition to ow distance is correlated with target concentration in our devices. This system can detect specic DNA targets in buffer and synthetic urine at 10 pg mL À1 levels.
In addition, our approach has a dynamic range of 10 6 and single-base mismatch specicity. Finally, DNA analogues of two miRNA biomarkers have been measured near clinically signi-cant levels, showing great promise for future medical application. We envision several improvements that can be incorporated into our nucleic acid analysis systems. Branched channel designs would allow different miRNAs to be quantied simultaneously from the same sample or for replicate tests to be done on the same biomarker. Branching channels having at least one segment lacking receptors could also be used to account for viscosity variability in specimens such as urine or blood. Designs with a microchannel extending to the edge of the device would allow direct sample loading without pipetting, thus facilitating point-of-care usage. These improvements for nucleic acid analysis in biological samples should further increase the versatility of our system for rapid and simple biomarker measurement.
Our approach could be extended to other target systems; in addition to miRNA, other RNA or DNA biomarkers could be targeted. Furthermore, our methods could be extended to detect small molecules, ions, or metals through aptamers. For example, surface-attached oligonucleotide receptors would bind to free aptamer, while aptamer bound to target would not hybridize, resulting in ow distance differences between the presence or absence of target. The work described herein, thus demonstrates excellent potential for biological target measurement in a point-of-care setting. 
